Papillary Craniopharyngioma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2025-02-18
Clinical Trial Update: Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma [Phase 2]
Phase 2 clinical trial evaluating vemurafenib and cobimetinib for BRAF V600E mutation-positive craniopharyngioma.